Subjective THC Effects Peaked After Plasma THC in an Intravenous Study
After intravenous THC, subjective effects peaked well after the plasma THC peak in an exploratory study. The result illustrates a timing mismatch between circulating concentration and reported experience, without providing a universal impairment curve.
An unusual route with repeated assessments
Twenty-five healthy volunteers received intravenous THC and six received saline placebo. Participants were not regular cannabis consumers. Investigators collected questionnaires repeatedly through 48 hours, assessing psychotropic and somatic experiences.
The intravenous route bypassed oral absorption and the inhalation process. Its timing cannot simply be assigned to an edible, vaporized product or smoked joint. The small, unequal groups and single-blind design also constrain interpretation.
Concentration and experience followed different schedules
Plasma concentrations peaked within approximately one to five minutes, while peak subjective effects generally occurred 45–60 minutes after administration. Many between-group effects were apparent for roughly 90–120 minutes; sleepiness and deactivation persisted longer.
Euphoria, irritation and headache did not show the same clear THC–placebo separation as many other reported effects. At 24 and 48 hours, the questionnaires did not show significant between-group differences. Neither statement means that every possible performance endpoint was tested or proved equivalent.
The practical meaning of a delayed peak
A falling blood concentration can coexist with effects that are still increasing or remain apparent. It would therefore be unsound to assume that a rapid concentration decline necessarily indicates immediate functional recovery.
These were subjective questionnaires, not a direct road-driving assessment. Their timing should be reported as such. Case-specific interpretation still requires the administered route, collection interval, observed behavior and any relevant performance evidence, rather than a numerical plasma result alone.
Related: Interpreting cannabinoid concentrations and functional effects.
Primary research
Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol – a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers. BMC Psychiatry (2024).



